Climb Bio CLYM 深 沪
已收盘 09-18 16:00:00 美东时间
14.05
-0.010
-0.07%
华盛通- 最 高14.44
- 今 开14.15
- 成交量 404.97万股
- 最 低 13.92
- 昨 收 14.06
- 总市值 8.07亿
- 52周最高 18.33
- 市盈率 静 --
- 换手率 7.05%
- 52周最低 1.54
- 委 比 -72.92%
- 总股本 5743.63万
- 历史最高 29.69
- 量 比 2.52
- 振 幅 3.70%
- 历史最低 1.05
- 每 手 1
- 风险率 4.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Small-cap stocks with strong momentum grades and triple-digit YTD gains
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for ServiceNow Inc (NYSE:NOW) from $150 to $170. BTIG analyst Allan Verkhovski ma...
09-08 21:07
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
Baird Maintains Outperform on Climb Bio, Raises Price Target to $25
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
09-04 02:01
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data
An announcement from Climb Bio ( ($CLYM) ) is now available. On September 3, 20...
09-03 20:17
Climb Bio rises after early-stage trial data for kidney disease drug
Climb Bio (CLYM) added more than 13% during premarket trading on Thursday after reporting data from a Phase 1 trial for CLYM116, its anti-APRIL monoclonal antibody targeting a kidney disease known as ...
09-03 19:51
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio, Inc. announced that its executive team will participate in two upcoming healthcare conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. Both sessions will be in Fireside Chat format. Live webcasts and replays will be available on the company's website. Climb Bio focuses on developing therapies for immune-mediated diseases, with a p...
09-02 11:00
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
